Discuva
Antibacterial discovery research has been driven, medically, commercially.
Financials
Estimates*
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 1.9m | 2.4m | <1m | - | - | - |
| % growth | - | 26 % | (90 %) | - | - | - |
| EBITDA | (1.6m) | <1m | (3.2m) | (3.3m) | (2.6m) | (2.6m) |
| % EBITDA margin | (82 %) | 25 % | (1318 %) | - | - | - |
| Profit | (2.0m) | <1m | (<1m) | (3.1m) | (2.4m) | (2.4m) |
| % profit margin | (104 %) | 10 % | (399 %) | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | £1.5m | Grant | |
| N/A | N/A | Acquisition | |
| Total Funding | €1.8m | ||
Related Content
Recent News about Discuva
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.